Canopy Growth Corp

Análisis de la acción Canopy Growth Corp (CGC)

$0.713

-0.022 (-3.06%)Al cierre

Loading chart…
Máximo
0.756
Apertura
0.752
Precio medio ponderado por volumen
0.72
Volumen
2.41M
Capitalización
508.24M
Mínimo
0.702
Importe
1.74M
EV/EBITDA, TTM
-6.00

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

Análisis de IA of Canopy Growth Corp (CGC)

Vender

Canopy Growth Corp is not a good buy right now due to its current price of 0.8271 and an RSI of 16.439, indicating it is oversold. The company is facing significant challenges, including a negative cash flow of CAD 25 million and a high insider selling rate of 187.19% over the last month, which raises red flags about investor confidence. The main risk is the ongoing cash flow losses, which have increased from CAD 10 million to CAD 25 million, indicating worsening financial health.

Métricas de valoración

El PER previsto actual de Canopy Growth Corp (CGC) es 20.37, frente a su media de 5 años de -1.24.

PER previsto

Muy sobrevalorado
Media 5A P/E
-1.24
P/E actual
20.37
Sobrevalorada
8.72
Infravalorada
-11.20

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-274.73
EV/EBITDA actual
-6.00
Sobrevalorada
449.33
Infravalorada
-998.79

Precio/ventas previsto

Valor razonable
Media 5A P/S
2.93
P/S actual
0.87
Sobrevalorada
5.23
Infravalorada
0.64

Escenarios de precio de Alphio AI para CGC

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%CGC

$1.78

Precio del escenario

B

Base

Base · 50%CGC

$1.69

Precio del escenario

B

Bajista

Bajista · 25%CGC

$1.41

Precio del escenario

Cronología de eventos

2026-09-28 (ET)

08:00:00

Canopy Growth Appoints Sebastian Blote as Country Manager for Germany

08:00:00

Canopy Growth Appoints Sebastian Blote as Country Manager for Germany

2026-09-22 (ET)

08:00:00

Canopy Growth Supplies Medical Cannabis Flowers to the UK

2026-09-08 (ET)

08:00:00

Canopy Growth Expands Medical Cannabis Portfolio in Australia

2026-08-07 (ET)

07:30:00

Company Reports Q1 Revenue of C$100.4M

Noticias

Preguntas frecuentes sobre CGC, respondidas por Alphio AI

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Canopy Growth Corp is not a good buy right now due to its current price of 0.8271 and an RSI of 16.439, indicating it is oversold. The company is facing significant challenges, including a negative cash flow of CAD 25 million and a high insider selling rate of 187.19% over the last month, which raises red flags about investor confidence. The main risk is the ongoing cash flow losses, which have increased from CAD 10 million to CAD 25 million, indicating worsening financial health.

Comunidad

Más ↗
0xSkewfalcon27/9/2026

As mid-term elections approach and marijuana legalization comes up for debate again, $CGC is a chart worth watching. A large triangle pattern is close to a breakout. If it can reclaim its 50 DMA, there could be upside ahead 📈🌿 $1+ looks fairly likely again in the near future.

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar